Menu
21/09/2004
NI patients being contacted over vCJD risk
A small number of people in Northern Ireland are to be contacted about the possibility that they may have an increased risk of developing the human form of CJD.
A number of patients have been written to, informing them that, because they have received certain batches of plasma products in the past, they are potentially at a small increased risk of infection with the vCJD agent.
It is part of a UK-wide patient notification exercise announced by the Department of Health in Whitehall which relates to the possible transmission of variant Creutzfeldt-Jakob Disease (vCJD) through blood products, announced by Health Secretary, John Reid, last week.
The advice is highly precautionary and is based on recommendations made by the expert vCJD Incidents Panel.
Patients (and their healthcare professionals) are being advised that they have, in the past, received batches of plasma products which were derived from blood donated from someone who has later gone on to develop vCJD. As a precautionary measure, a number of steps should be taken to reduce any possible onward patient-to-patient transmission of vCJD.
Commenting on the further precautionary measures the Northern Ireland's Chief Medical Officer, Dr Henrietta Campbell, said: “Every possible precautionary measure is being taken to protect patient safety and ensure the safety of blood. A small number of people have been identified by this exercise and may be exposed to a very low risk of vCJD. I would stress that even if someone is identified as ‘at-risk’, it does not mean that they will develop vCJD.
“The thousands of people who have received a blood transfusion are not affected and have no cause for concern. It is relevant only to people who may have been treated with certain batches of some products made from plasma sourced from the UK. This small group of people are being informed.
“In Northern Ireland, there are about 370 people who suffer from bleeding disorders. Only a small number will have received implicated plasma products. Likewise, of the 94 people with primary immunodeficiency disorders few, if any, will have received the implicated products."
Any member of the public who has general concerns should contact the DHSSPS regional helpline on 028 9076 5725.
(MB/GMCG)
A number of patients have been written to, informing them that, because they have received certain batches of plasma products in the past, they are potentially at a small increased risk of infection with the vCJD agent.
It is part of a UK-wide patient notification exercise announced by the Department of Health in Whitehall which relates to the possible transmission of variant Creutzfeldt-Jakob Disease (vCJD) through blood products, announced by Health Secretary, John Reid, last week.
The advice is highly precautionary and is based on recommendations made by the expert vCJD Incidents Panel.
Patients (and their healthcare professionals) are being advised that they have, in the past, received batches of plasma products which were derived from blood donated from someone who has later gone on to develop vCJD. As a precautionary measure, a number of steps should be taken to reduce any possible onward patient-to-patient transmission of vCJD.
Commenting on the further precautionary measures the Northern Ireland's Chief Medical Officer, Dr Henrietta Campbell, said: “Every possible precautionary measure is being taken to protect patient safety and ensure the safety of blood. A small number of people have been identified by this exercise and may be exposed to a very low risk of vCJD. I would stress that even if someone is identified as ‘at-risk’, it does not mean that they will develop vCJD.
“The thousands of people who have received a blood transfusion are not affected and have no cause for concern. It is relevant only to people who may have been treated with certain batches of some products made from plasma sourced from the UK. This small group of people are being informed.
“In Northern Ireland, there are about 370 people who suffer from bleeding disorders. Only a small number will have received implicated plasma products. Likewise, of the 94 people with primary immunodeficiency disorders few, if any, will have received the implicated products."
Any member of the public who has general concerns should contact the DHSSPS regional helpline on 028 9076 5725.
(MB/GMCG)
Related Northern Ireland News Stories
Click here for the latest headlines.
28 November 2002
Patients warned after blood donor's CJD diagnosis
There are concerns that a small number of haemophiliacs in Northern Ireland and Scotland may have received blood products from a donor who later was diagnosed with variant Creutzfeld-Jacob disease (vCJD). Health agencies in Scotland have written to patients warning them that they may have been given treatments derived from the donor's blood.
Patients warned after blood donor's CJD diagnosis
There are concerns that a small number of haemophiliacs in Northern Ireland and Scotland may have received blood products from a donor who later was diagnosed with variant Creutzfeld-Jacob disease (vCJD). Health agencies in Scotland have written to patients warning them that they may have been given treatments derived from the donor's blood.
15 November 2024
New Pathway To Support Young People With Diabetes
Health Minister Mike Nesbitt has welcomed the launch of a new Regional Young Adults' Progression Pathway designed to support young people with Type 1 diabetes as they transition to adult services.
New Pathway To Support Young People With Diabetes
Health Minister Mike Nesbitt has welcomed the launch of a new Regional Young Adults' Progression Pathway designed to support young people with Type 1 diabetes as they transition to adult services.
20 November 2024
Hard-Hitting Road Safety Message Delivered To Young People
Over 800 young people from schools in Lisburn and Castlereagh attended a hard-hitting road safety message at the PSNI Road Safe Roadshow on 19 November. The roadshow, supported by AXA Insurance and the Northern Ireland Road Safety Partnership, aims to educate young drivers about the dangers of irresponsible driving.
Hard-Hitting Road Safety Message Delivered To Young People
Over 800 young people from schools in Lisburn and Castlereagh attended a hard-hitting road safety message at the PSNI Road Safe Roadshow on 19 November. The roadshow, supported by AXA Insurance and the Northern Ireland Road Safety Partnership, aims to educate young drivers about the dangers of irresponsible driving.
10 January 2003
vCJD teenager begins controversial new treatment
A teenager from Northern Ireland who is suffering from vCJD has started to receive a controversial new treatment which may slow progress of the disease. Jonathan Simms, 18, from Belfast, and another patient, who cannot be named for legal reasons, where taken by their families to an NHS trust to get the treatment approved.
vCJD teenager begins controversial new treatment
A teenager from Northern Ireland who is suffering from vCJD has started to receive a controversial new treatment which may slow progress of the disease. Jonathan Simms, 18, from Belfast, and another patient, who cannot be named for legal reasons, where taken by their families to an NHS trust to get the treatment approved.
17 December 2002
NI vCJD victim given go-ahead for drug therapy
In a landmark ruling, the High Court in London has found that a Belfast teenager who is suffering from vCJD – the human form of Mad Cow Disease – can receive treatment from experimental drug treatment, despite its never having been tested on humans before.
NI vCJD victim given go-ahead for drug therapy
In a landmark ruling, the High Court in London has found that a Belfast teenager who is suffering from vCJD – the human form of Mad Cow Disease – can receive treatment from experimental drug treatment, despite its never having been tested on humans before.
-
Northern Ireland WeatherThis Evening and Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
